UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 59

Sortiert nach

Evidence of Extrapancreatic Glucagon Secretion in Man

Diabetes (New York, N.Y.), 2016-03, Vol.65 (3), p.585-597

2016

Link zum Volltext

Verfügbarkeit prüfen

The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion-A Review

International journal of molecular sciences, 2019-08, Vol.20 (17), p.4092

2019

Link zum Volltext

Verfügbarkeit prüfen

The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes

American journal of physiology: endocrinology and metabolism, 2011-06, Vol.300 (6), p.E1038-E1046

2011

Link zum Volltext

Verfügbarkeit prüfen

Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat

Frontiers in endocrinology (Lausanne), 2021-01, Vol.11, p.617400-617400

2021

Link zum Volltext

Verfügbarkeit prüfen

Glucagon and Type 2 Diabetes: the Return of the Alpha Cell

Current Diabetes Reports, 2014-12, Vol.14 (12), p.555-555, Article 555

2014

Link zum Volltext

Verfügbarkeit prüfen

A glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experiment

Frontiers in physiology, 2022-09, Vol.13, p.911616-911616

2022

Link zum Volltext

Verfügbarkeit prüfen

Associations of hypoglycemia, glycemic variability and risk of cardiac arrhythmias in insulin-treated patients with type 2 diabetes: a prospective, observational study

Cardiovascular diabetology, 2021-12, Vol.20 (1), p.241-241, Article 241

2021

Link zum Volltext

Verfügbarkeit prüfen

Mechanisms of the incretin effect in subjects with normal glucose tolerance and patients with type 2 diabetes

PloS one, 2013-09, Vol.8 (9), p.e73154-e73154

2013

Link zum Volltext

Verfügbarkeit prüfen

The effect of exogenous glucagon on circulating amino acids in individuals with and without type 2 diabetes and obesity

Endocrine Connections, 2024-03, Vol.13 (3), p.1-7

2024

Link zum Volltext

Verfügbarkeit prüfen

No effect of the turmeric root phenol curcumin on prednisolone-induced glucometabolic perturbations in men with overweight or obesity

Endocrine Connections, 2023-04, Vol.12 (4), p.1-14

2023

Link zum Volltext

Verfügbarkeit prüfen

Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals

American journal of physiology: Gastrointestinal and liver physiology, 2019-04, Vol.316 (4), p.G462-G472

2019

Link zum Volltext

Verfügbarkeit prüfen

The alpha-cell as target for type 2 diabetes therapy

The review of diabetic studies, 2011, Vol.8 (3), p.369-381

2011

Link zum Volltext

Verfügbarkeit prüfen

An extended minimal model of OGTT: estimation of α- and β-cell dysfunction, insulin resistance, and the incretin effect

American journal of physiology: endocrinology and metabolism, 2024-02, Vol.326 (2), p.E182

2024

Link zum Volltext

Verfügbarkeit prüfen

Impaired Regulation of the Incretin Effect in Patients with Type 2 Diabetes

The journal of clinical endocrinology and metabolism, 2011-03, Vol.96 (3), p.737-745

2011

Link zum Volltext

Verfügbarkeit prüfen

No detectable effect of a type 2 diabetes-associated TCF7L2 genotype on the incretin effect

Endocrine Connections, 2020-12, Vol.9 (12), p.1221-1232

2020

Link zum Volltext

Verfügbarkeit prüfen

244-OR: Signs of Glucagon Resistance after a Two-Week Hypercaloric Diet Intervention

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Link zum Volltext

Verfügbarkeit prüfen

Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects With Hepatic Steatosis

Diabetes (New York, N.Y.), 2020-06, Vol.69 (6), p.1090-1099

2020

Link zum Volltext

Verfügbarkeit prüfen

Long-acting amylin analogues for the management of obesity

Current opinion in endocrinology, diabetes, and obesity, 2022-04, Vol.29 (2), p.183

2022

Link zum Volltext

Verfügbarkeit prüfen

Glucose-Lowering Effects and Low Risk of Hypoglycemia in Patients With Maturity-Onset Diabetes of the Young When Treated With a GLP-1 Receptor Agonist: A Double-Blind, Randomized, Crossover Trial

Diabetes care, 2014-07, Vol.37 (7), p.1797-1805

2014

Link zum Volltext

Verfügbarkeit prüfen

Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals

Diabetologia, 2014-08, Vol.57 (8), p.1720-1725

2014

Link zum Volltext

Verfügbarkeit prüfen

The effect of curcumin on hepatic fat content in individuals with obesity

Diabetes, obesity & metabolism, 2022-11, Vol.24 (11), p.2192-2202

2022

Link zum Volltext

Verfügbarkeit prüfen

Glucagonostatic Potency of GLP-1 in Patients With Type 2 Diabetes, Patients With Type 1 Diabetes, and Healthy Control Subjects

Diabetes (New York, N.Y.), 2021-06, Vol.70 (6), p.1347-1356

2021

Link zum Volltext

Verfügbarkeit prüfen

Glucagon Clearance is Preserved in Type 2 Diabetes

Diabetes (New York, N.Y.), 2022-01, Vol.71 (1), p.73-82

2022

Link zum Volltext

Verfügbarkeit prüfen

1613-P: Feasibility of Time-Restricted Eating in the Treatment of Type 2 Diabetes—The RESET2 Pilot Study

Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 59

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54)
Mit Volltextzugriff
(50)

Publikationsform

Artikel
(59)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(43)
Life Sciences & Biomedicine
(42)
Humans
(35)
Endocrinology & Metabolism
(30)
Diabetes
(24)
Glucose
(23)
Male
(20)
Diabetes Mellitus
(18)
Middle Aged
(17)
Glucagon
(16)
Insulin
(16)
Female
(15)
Adult
(13)
Type 2 Diabetes
(13)
Diabetes Mellitus, Type 2 - Metabolism
(12)
Glucose Tolerance Test
(12)
Insulin Resistance
(12)
Obesity
(12)
Aged
(9)
Blood Glucose - Metabolism
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Evidence of Extrapancreatic Glucagon Secretion in Man

The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion-A Review

The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes

Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat

Glucagon and Type 2 Diabetes: the Return of the Alpha Cell

A glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experiment

Associations of hypoglycemia, glycemic variability and risk of cardiac arrhythmias in insulin-treated patients with type 2 diabetes: a prospective, observational study

Mechanisms of the incretin effect in subjects with normal glucose tolerance and patients with type 2 diabetes

The effect of exogenous glucagon on circulating amino acids in individuals with and without type 2 diabetes and obesity

No effect of the turmeric root phenol curcumin on prednisolone-induced glucometabolic perturbations in men with overweight or obesity

One Year’s Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial

Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals

The alpha-cell as target for type 2 diabetes therapy

An extended minimal model of OGTT: estimation of α- and β-cell dysfunction, insulin resistance, and the incretin effect

Impaired Regulation of the Incretin Effect in Patients with Type 2 Diabetes

No detectable effect of a type 2 diabetes-associated TCF7L2 genotype on the incretin effect

244-OR: Signs of Glucagon Resistance after a Two-Week Hypercaloric Diet Intervention

Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects With Hepatic Steatosis

Long-acting amylin analogues for the management of obesity

Glucose-Lowering Effects and Low Risk of Hypoglycemia in Patients With Maturity-Onset Diabetes of the Young When Treated With a GLP-1 Receptor Agonist: A Double-Blind, Randomized, Crossover Trial

Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals

The effect of curcumin on hepatic fat content in individuals with obesity

Glucagonostatic Potency of GLP-1 in Patients With Type 2 Diabetes, Patients With Type 1 Diabetes, and Healthy Control Subjects

Glucagon Clearance is Preserved in Type 2 Diabetes

1613-P: Feasibility of Time-Restricted Eating in the Treatment of Type 2 Diabetes—The RESET2 Pilot Study

Suchergebnisse filtern